Summary
The publisher's Medical Devices sector report, “Ovarian Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2020" provides comprehensive information about the Ovarian Cancer Diagnostic Tests pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
Ovarian Cancer Diagnostic Tests include assays of mostly antibodies released in response to a ovarian cancer and cancer-causing proteins.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
Scope
Reasons to Buy
The report enables you to -
The publisher's Medical Devices sector report, “Ovarian Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2020" provides comprehensive information about the Ovarian Cancer Diagnostic Tests pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
Ovarian Cancer Diagnostic Tests include assays of mostly antibodies released in response to a ovarian cancer and cancer-causing proteins.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
Scope
- Extensive coverage of the Ovarian Cancer Diagnostic Tests under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Ovarian Cancer Diagnostic Tests and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved/Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment/industry
Reasons to Buy
The report enables you to -
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of Ovarian Cancer Diagnostic Tests under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product’s current stage of development, territory and estimated launch date
Table of Contents
1 Table of Contents
3 Products under Development
4 Ovarian Cancer - Pipeline Products under Development by Companies
7 Appendix
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 2cureX AB
- A&G Pharmaceutical Inc
- AB ANALITICA srl
- Accudava Inc
- Adaptive Biotechnologies Corp
- Almac Diagnostic Services Ltd
- Angle Biosciences Inc
- Anixa Diagnostics Corporation
- AroCell AB
- Arrayit Corporation
- Aspira Labs
- Aurelium BioPharma Inc.
- Avant Diagnostics Inc
- Ayanda Biosystems SA (Inactive)
- BARD1 Life Sciences Ltd
- Becton Dickinson and Co
- BioFluidica Microtechnologies LLC
- Bioindustry Park Silvano Fumero SpA
- Brigham and Women's Hospital
- Captis Biotechnology Inc
- Celcuity Inc
- Celula Inc
- Ceres Nanosciences Inc
- Chronix Biomedical Inc
- Clarient Inc
- ClavGen Therapeutics LLC
- Cleveland Diagnostics Inc.
- Courtagen Life Sciences Inc
- Dana-Farber Cancer Institute Inc
- Diazyme Laboratories Inc
- Entopsis LLC
- Eventus Diagnostics Inc (Inactive)
- Exact Sciences Corp
- Exiqon AS
- Exosomics Siena SpA
- Fahy Gurteen UK Ltd
- French National Institute of Health and Medical Research
- Ganymed Pharmaceuticals AG
- Georgia Institute of Technology
- Gina-Life Diagnostics Ltd
- GlycoZym USA Inc
- H. Lee Moffitt Cancer Center & Research Institute Inc
- HealthTell Inc
- Hide and Seq
- Hudson Institute of Medical Research
- Ikonisys Inc
- INEX Innovate Pte Ltd
- InterGenetics Inc
- InterVenn BioSciences
- Johns Hopkins University
- KIYATEC Inc
- Lab Discoveries Ltd
- Laboratorios SALVAT SA
- Louisville Bioscience Inc (Inactive)
- MabCure Inc
- Massachusetts Institute of Technology
- MDNA Life Sciences Inc
- Metabolon Inc
- Milagen Inc
- MyCartis NV
- Nagoya University
- Nanostics Inc
- Novel Bio-spectrum Technologies Inc (Inactive)
- Olink Proteomics AB
- Olympia Diagnostics Inc
- Oncgnostics GmbH
- Oncimmune (USA) LLC
- Oncology Venture U.S. Inc
- Orion Genomics LLC
- OTraces Inc
- Peregrine Pharmaceuticals, Inc.
- Peri Rx Inc
- Precision Biologics Inc
- Preora Healthcare Inc
- Princess Margaret Cancer Centre
- Protagen AG
- Proteomika (Inactive)
- Provista Diagnostics Inc
- Queen's University Belfast
- Rosetta Genomics Ltd
- Shenzhen Mindray Bio-Medical Electronics Co Ltd
- SomaLogic Inc
- Soricimed Biopharma Inc
- Stage I Diagnostics Inc
- StageZero Life Sciences Ltd
- SurExam Life Science & Technology Co.
- Taizhou ZECEN Biotech Co Ltd
- Target Discovery Inc
- Teva Pharmaceutical Industries Ltd
- The University of Manchester
- Tradewind BioScience Inc
- Treos Bio Inc
- University of Adelaide
- University of Arkansas for Medical Sciences
- University of California San Diego
- University of Chicago
- University of Montreal
- University of Pittsburgh
- University of South Florida
- University of Texas MD Anderson Cancer Center
- US Biomarkers Inc
- Vermillion Inc
- Vitruvian Biomedical Inc
- Wistar Institute
- Yale University
- ZORA Biosciences Oy